Till Uhlig
Professor
https://orcid.org/0000-0002-6881-9552
https://orcid.org/0000-0002-6881-9552
Education
- Dr. Med at the Faculty of Medicine, University of Oslo (1996)
- Specialist in rheumatology (2000)
- Doctoral degree at the Faculty of Medicine, University of Oslo
Position
- Section chief/Senior researcher at the Department of Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital
- Professor II at the Department of Clinical Medicine, University of Oslo
Field of interest
- Clinical rheumatology
- Uric acid gout
- Rheumatoid arthritis
- Osteoarthritis
- Rehabilitation
Other
- Leader of work package 6 in REMEDY (Long-term follow-up)
visiting address
Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo
Postal address
Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo
Projects
WP1 - Optimized medical interventions
ARCTIC
Remission in patients with rheumatoid arthritis: a randomized controlled trial investigating the use of ultrasound in clinical follow-up
Project Manager:
Espen A. Haavardsholm
WP6 - Dechiphering long-term outcomes
NOECON
Health economics in the treatment of inflammatory arthritis diseases
Project Manager:
Sell Aarrestad Provan
WP1 - Optimized medical interventions
NORTH STAR
The Nordic study of strategy tests and registries for rheumatic diseases
Project Manager:
Espen A. Haavardsholm
WP3 - Pain mechanisms and management
Rehab Benefit
Specialized rehabilitation at private rehabilitation institutions
Project Manager:
Rikke Helene Moe
Project Manager:
Till Uhlig
Project Manager:
Nina ØsteråsPublications
Publications taken from the National Science Archive (NVA):
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomized controlled, non-inferiority trial
Kaja Eriksrud Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad
The Lancet Rheumatology
2024
Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis
Jianyang Liu, Helena Idborg, Marina Korotkova, Kristina Lend, Ronald van Vollenhoven, Jon Lampa
Arthritis Research & Therapy
2024
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomized controlled trial
Kristina Lend, Jon Lampa, Leonid Padyukov, Merete Lund Hetland, Marte Schrumpf, Dan C Nordström
Annals of the Rheumatic Diseases
2024
Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials
Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Kaja Eriksrud Kjørholt, Lena Bugge Nordberg, Tillmann Uhlig
RMD Open
2024
Circulating Baseline CXCR3 + Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis
Julia M. Scheffler, Christina Drevinge, Catharina Lindholm, Inger Gjertsson, Kristina Lend, Merete Lund Hetland
ACR Open Rheumatology
2024
Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Åse Lexberg
Annals of the Rheumatic Diseases
2023
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomized controlled NORD-STAR trial
Mikkel Østergaard, Ronald F Van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf, Dan C Nordström
Annals of the Rheumatic Diseases
2023
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomized controlled trial
Kristina Lend, Ronald F van Vollenhoven, Jon Lampa, Merete Lund Hetland, Espen A. Haavardsholm, Dan Nordström
The Lancet Rheumatology
2022
Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
Hilde Berner Hammer, Silvia Christin Hellerud Rollefstad, Anne Grete Semb, Gro Elisabeth Jensen, Lars Fridtjof Karoliussen, L Terslev
RMD Open
2022
Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.
Marit Stockfelt, Anna-Carin Lundell, Merete Lund Hetland, Mikkel Østergaard, Till Uhlig, Marte Schrumpf
Arthritis Research & Therapy
2021
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumor necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
Ingrid Egeland Christensen, Siri Lillegraven, Mielnik Pawel, Gunnstein Bakland, Liz Paucar Loli, Joseph Sexton
Annals of the Rheumatic Diseases
2021
12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: Achievements of the urate target levels and predictors of obtaining this target
Till Uhlig, Lars Fridtjof Karoliussen, Joseph Sexton, Tove Borgen, Espen A. Haavardsholm, Tore Kristian Kvien
RMD Open
2021
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
Siri Lillegraven, Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Hallvard Fremstad
Journal of the American Medical Association (JAMA)
2021
Validity and diagnostic performance of fluorescence optical imaging measuring synovitis in hand osteoarthritis: baseline results from the Nor-Hand cohort
Øystein Gunnar Maugesten, Alexander Mathiessen, Hilde Berner Hammer, Sigrid Valen Hestetun, Tore Kristian Kvien, Till Uhlig
Arthritis Research & Therapy
2020
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial
Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin, Dan C. Nordström, Michael Nurmohamed, Bjorn Gudbjornsson
The BMJ
2020
EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyzes of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries
Rachelle Meisters, Polina Putrik, Sofia Ramiro, Monika Hifinger, Andras P. Keszei, Yvonne van Eijk-Hustings
Annals of the Rheumatic Diseases
2020
Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study
Hilde Berner Hammer, Lars Fridtjof Karoliussen, Lene Terslev, Espen A Haavardsholm, Tore Kristian Kvien, Till Uhlig
Annals of the Rheumatic Diseases
2020
Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis
Hilde Berner Hammer, Brigitte Michelsen, Joe Sexton, Till Uhlig, Sella Aarrestad Provan
Clinical Rheumatology
2020
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.
Polina Putrik, Sofia Ramiro, Francis Guillemin, Márta Péntek, Francisca Sivera, Tuulikki Sokka
Annals of the Rheumatic Diseases
2019
Swollen, but not tender joints, are independently associated with ultrasound synovitis: Results from a longitudinal observational study of patients with established rheumatoid arthritis
Hilde Berner Hammer, Brigitte Michelsen, Joseph Sexton, Ida Kristin Haugen, Sella Aarrestad Provan, Espen A. Haavardsholm
Annals of the Rheumatic Diseases
2019
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
Lena Kristine Bugge Nordberg, Siri Lillegraven, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Elisabeth Lie
RMD Open
2018
The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyzes from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen
Lena Kristine Bugge Nordberg, Siri Lillegraven, Anna-Birgitte Aga, Joseph Sexton, Elisabeth Lie, Hilde Berner Hammer
Arthritis & Rheumatology
2018
Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes
Nina Beate Paulshus Sundlisæter, Anna-Birgitte Aga, Inge Christoffer Olsen, Hilde Berner Hammer, Till Uhlig, Desirée van der Heijde
Annals of the Rheumatic Diseases
2018
Health-related quality of life in patients with psoriatic and rheumatoid arthritis: Data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls
Brigitte Michelsen, Till Uhlig, Joseph Sexton, Desirée van der Heijde, Hilde Berner Hammer, Eirik Kristianslund
Annals of the Rheumatic Diseases
2018
The eumusc.net standards of care for rheumatoid arthritis: Importance and current implementation according to patients and healthcare providers in the Netherlands
Monika Hifinger, Sofia Ramiro, Polina Putrik, Yvonne van Eijk-Hustings, Anthony Woolf, Josef Sebastian Smolen
Clinical and Experimental Rheumatology
2018
Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: Study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study
Daniel Glinatsi, Marte Schrumpf, Anna Rudin, Dan C. Nordström, Espen A. Haavardsholm, Björn Gudbjörnsson
Trials
2017
Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria
Lena Kristine Bugge Nordberg, Siri Lillegraven, Elisabeth Lie, Anna-Birgitte Aga, Inge Christoffer Olsen, Hilde Berner Hammer
Annals of the Rheumatic Diseases
2017
Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register
Sella Aarrestad Provan, Inge Christoffer Olsen, Cathrine Austad, Glenn Haugeberg, Tore Kristian Kvien, Till Uhlig
Seminars in Arthritis & Rheumatism
2017
Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD
Polina Putrik, Sofia Ramiro, Elisabeth Lie, Andras P. Keszei, Tore Kristian Kvien, Desirée van der Heijde
Rheumatology
2016